Can a new pill tame advanced breast cancer?

NCT ID NCT06047184

NEW Completed Disease control Sponsor: BeBetter Med Inc Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This early-stage trial is testing an experimental drug called BEBT-209 in women with advanced HR+/HER2- breast cancer. The study aims to find the safest dose and see how well the drug works, both on its own and when combined with standard hormone therapies like letrozole or fulvestrant. Participants will receive the drug in cycles, and researchers will monitor side effects, drug levels in the body, and any signs that the cancer shrinks or stops growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BEBT-209 capsules, given alone or with letrozole or fulvestrant
What this could lead to: If successful, this could lead to a new treatment option for advanced HR+/HER2- breast cancer, potentially slowing disease progression.
What could go wrong: This is an early-phase trial, so the drug may not work as hoped or may cause side effects. The results will only show safety and preliminary efficacy, not a proven cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Xiangya Hospital Central South University

Changsha, Hunan, 410013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.